SHENZHEN, China, Jan. 13, 2025 /PRNewswire/ — Addentax Group Corp. (“Addentax” or the “Company”) (Nasdaq: ATXG), an integrated service provider focusing on garment manufacturing, logistics services, property management, and subleasing, has announced that Addentax has purchased 3,750,000 common shares in Well Information Technology Corporation (“Well InfoTech”), a company incorporated under the jurisdiction of the State of Nevada. Well InfoTech and its subsidiaries are headquartered in Hangzhou, People’s Republic of China.

Well InfoTech’s core expertise lies in providing a comprehensive range of marketing solutions, including both online and offline marketing plans. Well InfoTech mainly serves store owners and managing personnel in fresh food industry across People’s Republic of China, mainly targeting large cities in China, such as Hangzhou, Beijing, and Heilongjiang. Their mission is to deliver comprehensive and tailored marketing solutions that enhance the visibility and profitability of fresh food store owners. Well InfoTech is committed to leveraging the latest digital tools and traditional marketing techniques to connect businesses with their customers, build lasting relationships, and promote a culture of healthy eating.

Pursuant to the Securities Purchase Agreement, the Company acquired 2.5% equity stake in Well InfoTech for a total consideration of USD $750,000. The investment was made in cash.

About Addentax Group Corp.

Addentax Group Corp. is an integrated service provider specializing in garment manufacturing, logistics services, and property management and subleasing. For more information about the Company, please visit the website: https://www.addentax.com/.

Caution Concerning Forward Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements in nature within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, the Company’s and Well InfoTech’s expectations with respect to the Agreement, the valuation of Well InfoTech including the products it offers and the markets in which it operates, and the Company and Well InfoTech’s projected future results, and known and unknown risks and uncertainties which are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions are intended to identify such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to consider risk factors, including those described in the Company’s filings with the U.S. Securities and Exchange Commission, that may affect the Company’s future results. All forward-looking statements attributable to the Company and its subsidiaries or persons acting on their behalf are expressly qualified in their entirety by these risk factors. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Addentax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to (i) risks related to the purchase of shares of Well InfoTech’s common stock, including risks related to the Company’s ability to realize some or all of the anticipated benefits from the purchase of the shares of Well InfoTech’s common stock, and (ii) other risks as set forth from time to time in the Company’s filings with the U.S. Securities and Exchange Commission, including the factors described in detail in the “Risk Factors” section of Addentax’s Annual Report on Form 10-K for the year ended March 31, 2024. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur, except as may be required by law.

Company Contact:

Public Relations Contact:
Addentax Group Corp.
Phone: + (86) 755 86961 405
xinyee.lee@zgyingxi.com 

Investor Relations Contact:

Sherry Zheng
Weitian Group LLC
1-718-213-7386
shunyu.zheng@weitian-ir.com 

• Exhibition booth attracts 65,000 cumulative visitors, showcasing innovative mobility components
• Innovative technologies presented through a ‘User-Centric storytelling’ approach elicit strong acclaim, inquiries from visiting customers ensue

SEOUL, South Korea, Jan. 13, 2025 /PRNewswire/ — On the 13th, LG Innotek (CEO Moon Hyuksoo) announced that it successfully staged its exhibition at CES 2025 held in Las Vegas, USA.

Situated at the entrance of the West Hall of the Las Vegas Convention Center (LVCC), LG Innotek’s exhibition booth attracted a steady stream of visitors from its opening on the first day of the CES event, on January 7th (local time).

During the four-day exhibition period that lasted until the 10th, more than 65,000 visitors were recorded at the LG Innotek booth. Many visitors showed great interest, leading to product inquiries and on-the-spot meeting requests.

A company representative said, “This year, we prominently displayed a 1,800-inch large-scale video advertisement in the Main Hall of the West Hall and a 9-meter-tall banner at the booth entrance, effectively enhancing brand awareness and exhibition promotion.”

At CES 2025, LG Innotek focused its exhibition on the theme of mobility to solidify its position as a ‘Total Solution Provider’ in the global market for future mobility.

In particular, LG Innotek designed its open booth with a sleek, futuristic black aesthetic, showcasing not only a future vehicle mockup but also its new brand identity, ‘ENABLE THE NEXT’, and the slogan, ‘YOUR ASPIRATION, OUR INNOVATION.’

At the center of the exhibition booth, the future vehicle mockup displayed 15 key components for sensing, communication, and lighting. Additionally, the high-value vehicle lighting module, Nexlide A+, which won the CES 2025 Innovation Award, garnered significant attention.

In the expanded private booth, which was 30% larger than the previous year, various innovative and integrated solutions combining optical, communication, and automotive technologies were presented through an immersive User-Centric storytelling approach, receiving positive feedback.

Among these, the RGB-IR In-Cabin Camera Module, unveiled for the first time at CES 2025, stood out. This camera can monitor driver conditions, such as detecting drowsiness, and alert the driver immediately.

Unlike conventional models, this new module features a 150-degree field of view, enabling simultaneous monitoring of the driver, front passenger, and rear passengers. It integrates a 5-megapixel RGB camera, an IR camera for low-light environments, and a 3D camera that supports facial recognition for functions like login and payment.

When a driver logs in using facial recognition, settings such as radio channels and air conditioning levels, adjusted by previous drivers, are automatically switched to the new driver’s preferences. A North American customer said, “It’s impressive how such advanced features, which enhance convenience for drivers, are incorporated into a single small camera module.”

The innovation of ‘Nexlide Vision,’ developed with LG Innotek’s proprietary vehicle lighting technology, also drew attention. Combining pixel lighting and smart film technology, this product can implement pixels, surfaces, and lines simultaneously.

For instance, by writing a desired message on the adjacent pad, the text instantly appears on the vehicle’s lighting grill. This innovative application demonstrated how advanced communication capabilities can be integrated into vehicle lighting.

A customer who experienced Nexlide Vision’s lettering feature said, “If an emergency stop is required while driving, it’s possible to use Nexlide Vision to communicate specific reasons to following vehicles, potentially preventing accidents. LG Innotek’s technology is truly remarkable.”

Furthermore, LG Innotek’s comprehensive lineup of mobility solutions, including the Next-Generation Digital Key Solution, Vehicle AP Module, All-Weather Camera Solution, and the groundbreaking B-Link, which combines a wireless Battery Management System (BMS) with a Battery Junction Box (BJB), were prominently showcased at CES 2025.

CEO Moon Hyuksoo stated, “Through CES 2025, LG Innotek has further strengthened its position as a leader in future mobility components. We will continue to deliver innovative solutions that provide differentiated value to customers and grow as the reliable technology partner enabling our customer’s aspiration.”

– Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine
– Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications

SEOUL, South Korea, Jan. 13, 2025 /PRNewswire/ — Since the COVID-19 pandemic, mRNA vaccines have been recognized as the most important platform for infectious disease prevention and continue to be utilized across various fields. However, concerns remain about the limitations of the technology, including the need for ultra-cold storage and side effects associated with lipid nanoparticles (LNP) required for mRNA delivery.

Recently, new platforms are emerging as alternatives to mRNA vaccines.

One such platform is the Virus-Like Particle (VLP) vaccine technology. While not as widely known as mRNA vaccines, Ferritin based nano platform VLP vaccines have been noted for their potential to significantly enhance immune responses due to their structural stability. VLPs mimic the structural characteristics of target viruses, presenting antigens in a virus-like configuration. Particularly, the Ferritin based nano platform VLP vaccine is being evaluated as a powerful platform capable of accommodating multiple virus antigens simultaneously, making it suitable for addressing various mutations.

DXVX(180400) has recently acquired global development rights from Stanford University for an innovative universal coronavirus vaccine based on the Ferritin based nano platform VLP technology. Through the dedication and persuasive efforts of Chong-Yoon Lim, Chairman of the COREE Group and major shareholder of DXVX, this collaboration was established.

Ferritin, a protein that stores iron, can self-assemble into hollow spherical nanoparticles depending on pH conditions. Dx&Vx’s VLP vaccine utilizes this ferritin-based nanoparticle platform to display the spike protein of the coronavirus on its surface, making a universal coronavirus vaccine. The Ferritin-based VLP vaccine structurally mimics the size and shape of the COVID-19 virus, enabling the immune system to recognize it as the actual virus. This VLP vaccine can induce a strong cytotoxic T-cell response, effectively combating viral infections.

The human immune system defends against viral infections through both humoral and cellular immune responses, a process known as ‘cross-presentation.’ Vaccines that stimulate both immune systems simultaneously provide more robust and long-lasting immunity compared to vaccines that only induce antibody production.

Cytotoxic T cells, which play a critical role in destroying virus-infected or cancerous cells, do not directly recognize antigens. Instead, T cells only identify antigen fragments presented by major histocompatibility complex (MHC) molecules, thereby targeting and eliminating infected cells.

Notably, Dx&Vx’s vaccine is designed to strongly induce both humoral and cellular immune responses, making it superior to traditional antigen protein-based vaccines that primarily focus on humoral immunity. The Ferritin-based VLP vaccine, now preparing for global Phase 2 clinical trials, is expected to demonstrate superior immune induction effects compared to marketed vaccines.

According to animal studies conducted by the Walter Reed Army Institute of Research (WRAIR), the Ferritin-based VLP vaccine demonstrated neutralizing antibody levels more than ten times higher than those of mRNA vaccines. Additionally, the Wuhan Institute of Virology in China reported that the Ferritin-based VLP vaccine outperformed mRNA vaccines. Collectively, these findings indicate that the Ferritin-based VLP vaccine may offer superior protective effects compared to traditional vaccine platforms.

Moreover, this vaccine has demonstrated stability at room temperature for up to two weeks and has shown the ability to induce strong immune responses even in previously unexposed organisms. These characteristics distinguish it from mRNA-based vaccines. The platform has also been validated for its applicability in polyvalent vaccines for broad mutation coverage, offering versatility in administration routes and various other advantages.

Dx&Vx’s VLP universal coronavirus vaccine has already completed Phase 1 clinical trials in the United States and South Africa, where it was evaluated against mRNA vaccines for antibody titers and adverse effects. The results have confirmed the technological superiority of this vaccine platform.

The Ferritin platform-based VLP vaccine is expected to be extended for the development of vaccines against various lethal viruses, such as influenza and Ebola, playing a critical role in future pandemic responses.

A Dx&Vx representative stated, “The ultimate goal of the Ferritin platform-based VLP vaccine under development is to provide a safe, superior, and convenient vaccine that offers maximum protection against various deadly infectious diseases for humanity.”

STAMFORD, Conn., Jan. 13, 2025 /PRNewswire/ — Trillium Flow Technologies (“Trillium”), a portfolio company of First Reserve, and a global designer, manufacturer, and aftermarket services provider of highly engineered valves and pumps used in critical infrastructure sectors such as nuclear power, water, wastewater, and industrial processing, is pleased to announce the successful completion of its refinancing in December 2024.

The refinancing provides Trillium with extended maturity, enhanced liquidity, improved terms, and increased flexibility to support further M&A activity.

Kerem Yilmaz, Chief Financial Officer of Trillium, commented: “We are pleased to cap a successful 2024 with this significant milestone and to enter 2025 with strong momentum. We are excited about our new credit facility, which is led by funds managed by Blue Owl Capital Inc. (“Blue Owl”). We would also like to thank JP Morgan and BDTMSD for their continued commitment and support of our business. This refinancing positions us well to execute our organic growth strategy, which includes investing in innovation and operational excellence to better serve our customers. We aim to remain active in M&A as a leading player in the flow control industry.”

Matt Tier, Managing Director at Blue Owl, said: “Trillium has a long and successful track record as a global supplier and aftermarket service provider of mission-critical valves and pumps used in a variety of industries. We are excited to welcome Trillium as borrower in our direct lending portfolio and look forward to supporting Doug, Kerem and the rest of the leadership team as they execute on their growth strategy for the business in the years to come.”

Doug Kitani, Chief Executive Officer of Trillium, said: “I’d like to extend my deepest gratitude to our finance team, equity partner First Reserve, and our lead lender, Blue Owl, for their support throughout this successful refinancing, and I especially want to recognize our employees for their exceptional performance in 2024. This milestone reflects our collective dedication and positions Trillium for continued innovation, growth, and leadership in the global flow control industry.”

About Trillium Flow Technologies
Trillium Flow Technologies is a global designer, manufacturer, and aftermarket services provider specializing in highly engineered valves, pumps, and related products. Serving customers in critical infrastructure industries, Trillium is committed to delivering innovative solutions that enhance reliability, safety, and efficiency.

For more information, visit: www.trilliumflow.com.

About Blue Owl
Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives.

With $235 billion in assets under management as of September 30, 2024, we invest across three multi-strategy platforms: Credit, GP Strategic Capital, and Real Estate. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation.

Together with over 1,050 experienced professionals, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit www.blueowl.com.

About First Reserve:
First Reserve is a leading global private equity firm investing across diversified energy, utility, and industrial end-markets. Founded in 1983, First Reserve has more than 40 years of industry insight and has cultivated a differentiated network of global relationships. The firm has raised over $34 billion of aggregate capital and has developed operational expertise built from over 750 transactions, including platform investments and add-on acquisitions. For more information, visit www.firstreserve.com.

Media Contact
Chris Molineaux
Global Marketing and Communications Director, Trillium Flow Technologies
media@trilliumflow.com

The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS’ LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism.

DUBLIN, Calif. and JENA, Germany, Jan. 13, 2025 /PRNewswire/ — ZEISS Medical Technology announced today that the MEL^® 90 received approval from the U.S. Food and Drug Administration (FDA), giving the excimer laser technology simultaneous approval for all three major indications, including myopia, hyperopia and mixed astigmatism (a condition where both hyperopic and myopic correction is required). The ZEISS MEL 90 fully integrates into the Corneal Refractive Workflow to offer U.S. surgeons a fast, reliable, and streamlined surgery experience, complementing the VISUMAX^® 800 with SMILE^® pro from ZEISS to help further broaden a surgeon’s refractive business with improved patient attraction and positive clinical outcomes.

ZEISS MEL 90 Excimer Laser

“The increasing global adoption of laser vision correction reflects the advancements and positive impact the technology continues to have on the quality of life for patients,” says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. “With the integration of the ZEISS MEL 90, surgeons can confidently care for their patients with greater workflow efficiency and performance with enhanced outcomes.”

“ZEISS continues to break new ground as a leader in the LVC market, reflecting our ongoing commitment to and support of U.S. surgeons and patients with the latest refractive innovation that helps set practices apart and provides more options to more patients,” says Andrew Chang, Head of Global Sales for ZEISS Medical Technology. “With the availability of the ZEISS MEL 90 in the U.S. market, surgeons can now offer an integrated workflow of refractive technology to help reach new patients and provide excellent outcomes for them.”

“The FDA approval of the ZEISS MEL 90 excimer laser is a game changer for refractive surgery in the U.S. This advanced technology, with its Triple-A ablation algorithm and fast ablation speed, sets a new benchmark for precision, safety, and efficiency. I am particularly impressed by the system’s ability to simplify treatment planning while delivering highly predictable and tissue-conserving results. The integration of the ZEISS MEL 90 with the ZEISS VISUMAX 800 femtosecond laser opens new doors for streamlined workflows and optimal patient outcomes. This approval marks an exciting chapter for surgeons and patients alike,” says Dr. John Doane, Refractive Surgeon, Discover Vision Centers, Kansas City, MO.

Reliable Outcomes: The ZEISS MEL 90 offers Triple-A (Advanced Ablation Algorithm), which is a single ablation profile for a wide range of sphero-cylindrical (SCA) corrections that simplifies treatment planning. Triple-A offers a high degree of accuracy, reproducibility and predictability, as well as advantages such as tissue-saving ablation. Its preinstalled functions also offer surgeons optimal support for achieving excellent treatment results and gentle treatments of standard, higher and lower levels of ametropia and astigmatism.

Fast Ablation Speed: The ZEISS MEL 90 offers a truly customized power package. When performing LASIK for myopia at 500 Hz, the ZEISS MEL 90 can intra-operatively ablate 1 diopter in as little as 1.3 seconds.¹ Intuitive system guidance and speedy treatment planning allow for additional time savings. The ZEISS MEL 90 excimer laser technology is equipped with an active eye tracker which delivers an excellent response time, providing a high level of treatment safety with very stable results.

Easy to Use: New capabilities of the ZEISS MEL 90 excimer laser greatly simplify the interactions between the surgeon, the assisting staff and the system technology. The excimer laser can be configured to precisely match the surgeon and the OR team’s needs. The system’s simple, intuitive graphic user interface supports fast treatment procedures, and the touch screen can be flexibly positioned wherever it is needed to enable the surgeon to have good ergonomic sitting posture throughout an operation. A second, optional touch screen can be configured to optimally complement the treatment routine of the OR team. An HD video port, network printer connection, and PDF export capabilities offer additional workflow support.

With the ZEISS MEL 90, the company expands its offerings for U.S. refractive clinics and helps support the improvement of clinical outcomes and patient satisfaction through onboarding, training, service support and ZEISS Practice Development Consulting.

The ZEISS MEL 90 excimer laser is currently available in the U.S. For more information, visit www.zeiss.com/us/mel-90

¹LASIK myopia, optical zone 6 mm.

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

VANCOUVER, BC, Jan. 13, 2025 /PRNewswire/ — WAT Medical Enterprise collaborated with Concordia University and Mitacs Canada to conduct a study using ObeEnd, the neuromodulation device designed by WAT for weight and health management. The study revealed that electroacupuncture may help improve exercise performance and post-exercise recovery by reducing heart rate and perceived exertion during physical activity.

Published in the International Journal of Environmental Research and Public Health, the study highlights the potential benefits of this neuromodulation technology based on traditional Chinese medicine technique for enhancing participation in physical activity.

The research involved 32 healthy participants, who underwent electroacupuncture sessions targeting the PC6 acupuncture point over the course of one week. The study employed the YMCA submaximal bike test to measure cardiovascular responses, including heart rate, systolic blood pressure, and perceived exertion levels.

Key findings included a significant reduction in heart rate during the most challenging stage of the exercise test, as well as a decreased perception of effort across all stages. Additionally, participants experienced quicker post-exercise recovery, with systolic blood pressure notably lower five minutes after completing the test. The proposed mechanism of action is through the modulation of the rostral ventrolateral medulla (RVLM), a key area in the brainstem that regulates cardiovascular function and arterial blood pressure.

The study suggests that electroacupuncture could be particularly useful for populations struggling with sedentary lifestyles or exercise-induced fatigue. By making exercise feel easier, this technique could encourage greater adherence to fitness routines, promoting better long-term health outcomes.

Possible application in hypertension management could also be explored in future studies, as the proposed mechanism has the potential to down-regulate the sympathetic nervous system and reduce blood pressure.

References:

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC11507089/
2. www.watmedical.com
3. www.emeterm.com

SINGAPORE, Jan. 13, 2025 /PRNewswire/ — Platform tokens have gained increased attention in this bull market, with notable examples from leading exchanges. Amid this surge, WXT, the native token of WEEX Exchange, has seen extraordinary growth, climbing 101% within 24 hours on January 11.

This development coincides with WEEX’s ongoing global expansion. As a rapidly growing cryptocurrency exchange, WEEX continues to increase its presence in the competitive marketplace, with WXT emerging as an integral part of its ecosystem.

This surge comes as WEEX, continues to expand its global presence. WXT’s price trajectory reflects the growing influence of WEEX in the competitive cryptocurrency market.

WXT: Reflecting WEEX’s Rapid Growth

As Andrew Weiner, Vice President of WEEX, highlighted in a recent annual update, “WXT has achieved a price increase of nearly 450% since its issuance. And WXT’s trajectory mirrors WEEX’s incredible journey of growth.”

To further enhance its global outreach, WEEX has partnered with renowned football star Michael Owen as a brand ambassador. This collaboration aims to build increased brand visibility, positioning WEEX as a widespread and innovative platform in the cryptocurrency space.

According to the WEEX white paper, WXT’s ecosystem offers diverse utilities for its holders, including trading fee discounts, staking rewards, early access to new projects, and participation in airdrops. Additionally, WEEX has implemented a strategic buyback and burn mechanism, reducing WXT’s circulating supply as part of its ecosystem development strategy. These features position WXT as a multifunctional token that appeals to both active traders and long-term participants within the ecosystem.

Exchange Tokens and Their Growing Potential

This bull market has further cemented the role of platform tokens as integral components of exchange ecosystems. Platform tokens have shown their ability to enhance user engagement by offering features such as fee adjustments and access to platform-specific benefits. As WXT gains momentum, how will it evolve within the ecosystem and shape its role in the platform token landscape? While its recent performance is promising, only time will tell if WXT can achieve the same level of success as its peers.

About WEEX

Founded in 2018, WEEX Exchange swiftly rose to prominence as a key global player in the cryptocurrency sphere. Boasting a diverse selection of over 1,000 trading pairs and spearheading a zero trading fee initiative for new token introductions, WEEX Exchange has earned widespread recognition throughout the industry. Introducing “WEEX WE-Launch,” a portal to exciting opportunities that empower users to acquire WXT tokens and engage in exclusive token giveaways, signaling a new chapter of participation and empowerment. With an active user base exceeding 5 million, WEEX Exchange has solidified its standing as a top 5 platform on CoinMarketCap, underscoring its unwavering commitment to excellence.

For more information:

• Website: WEEX Exchange

SHANGHAI, Jan. 13, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR T-cell therapy targeting CD19/CD20, has administered the first dose to a patient in an investigator-initiated trial (IIT).

KJ-C2219 is developed based on CARsgen’s THANK-u Plus platform and is designed for the treatment of hematologic malignancies and autoimmune diseases. An investigator-initiated trial is ongoing in China to evaluate KJ-C2219 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).

About THANK-u Plus

CARsgen has developed the THANK-u Plus platform as an enhanced version of its proprietary THANK-uCAR^® allogeneic CAR-T technology to address the potential impact of NKG2A expression levels on therapeutic efficacy. THANK-u Plus demonstrates sustained expansion regardless of varying NKG2A expression levels on NK cells and exhibits significantly improved expansion compared to THANK-uCAR^®. Preclinical studies show that THANK-u Plus delivers superior antitumor efficacy in the presence of NK cells compared to THANK-uCAR^®. Allogeneic BCMA or dual-targeting CD19/CD20 CAR-T cells developed using this platform exhibit robust antitumor activity in the presence of NK cells, indicating that THANK-u Plus has broad potential for developing diverse allogeneic CAR-T therapies.

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company with operations in China and the U.S., focusing on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. CARsgen has established a comprehensive CAR T-cell research and development platform that covers target discovery, innovative CAR T-cell development, clinical trials, and commercial-scale production. Internally, CARsgen has developed novel technologies and a product pipeline with global rights to address significant challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. CARsgen’s mission is to become a global biopharmaceutical leader that provides innovative and differentiated cell therapies for cancer patients worldwide and makes cancer curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

Contact CARsgen

For more information, please visit https://www.carsgen.com/